TC, financing is the least of worry for ariad as some here are so fearful about. We have revenues in ponatinib, royalty payment from bellicum, royalty payment from Rida stent, royalty payment from argent technology (however small they may be), pona partnership in Japan soon, perhaps another pona partnership with a BP in one of Iclusig indications, perhaps another partnership in Nmole. When some of these possibilities could not be worked out, they could take out another loan. Three dozen indications from pona, God knows how many indications we will have from 113. I am okay with multiple partnerships, just not a BO. A BO of 20 is the worst thing for ariad investors in my opinion. With all these potentials and possibilities, HB can say "Houston we don't have a problem here"....jmo.
